The return of gemtuzumab ozogamicin: A humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and therapy, 2018 - Taylor & Francis
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and Therapy, 2018 - dovepress.com
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
[HTML][HTML] The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid …
PC Egan, JL Reagan - OncoTargets and therapy, 2018 - ncbi.nlm.nih.gov
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and Therapy, 2018 - search.proquest.com
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and therapy, 2018 - pubmed.ncbi.nlm.nih.gov
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.
PC Egan, JL Reagan - Oncotargets and Therapy, 2018 - europepmc.org
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody--drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
PC Egan, JL Reagan - OncoTargets and Therapy, 2018 - go.gale.com
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.
PC Egan, JL Reagan - OncoTargets & Therapy, 2018 - search.ebscohost.com
Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …